EyeGate Pharmaceuticals Lands $5,900,000 Series D Funding Round

  • Feed Type
  • Date
    1/6/2011
  • Company Name
    EyeGate Pharmaceuticals
  • Mailing Address
    100 Beaver Street Waltham, MA 02453
  • Company Description
    EyeGate Pharma is focused on replacing ocular injections and other invasive methods of ocular disease treatment. Our goal is to build a pipeline of safer, more effective and patient friendly ocular treatments based on our EyeGate II Delivery System.
  • Website
    http://www.eyegatepharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $5,900,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    The funds will be used to continue development of EGP-437 for the treatment of Dry EyeSyndrome (DES), an ocular surface irritation affecting several million men and women in theUnited States. EGP-437 is a dexamethasone derived corticosteroid solution speciallyformulated for delivery using the EyeGate® II Delivery System.
  • M&A Terms
  • Venture Investor
    Undisclosed

Trending on Xconomy